Treatment-resistant epilepsy and cannabis-based medicines

There are an estimated 100,000+ medical cannabis patients in the UK. Find out if you qualify

Treatment-resistant epilepsy and cannabis-based medicines

Treatment-resistant epilepsy and cannabis-based medicines - MCPH patient guide cover

Share This Story

Facebook-f Twitter Youtube Linkedin-in

Table of Contents

For treatment-resistant epilepsy, UK guidance is much narrower than many headlines make it sound. There is a licensed cannabidiol medicine, Epidyolex, with defined specialist uses in severe epilepsy contexts such as Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex. That is not the same as saying cannabis-based medicines are broadly proven for epilepsy, or that an epilepsy diagnosis on its own means someone may qualify for a private cannabis prescription.

This is a red-risk guide for patient and editorial review. It is not medical advice. Epilepsy treatment decisions need a neurologist or epilepsy specialist who can look at seizure type, syndrome, previous medicines, current medicines, age, liver risk, side effects, pregnancy or fertility context, mental health, impairment and monitoring.

For the wider UK route, start with the MCPH patient guide. For the access boundary, read medical cannabis qualifying conditions. For general safety context, read medical cannabis side effects.

The short answer

Epidyolex is the main cannabis-based medicine to understand in severe treatment-resistant epilepsy. It is a purified cannabidiol medicine with a UK product licence for specific seizure contexts, and NICE has technology appraisal guidance for its use in defined groups.

That does not make other cannabis oils, flower, extracts or THC-containing products evidence-equivalent for epilepsy. NICE NG144 does not support a broad recommendation for unlicensed cannabis-based medicinal products for epilepsy. NHS England and professional guidance keep prescribing within specialist, evidence-aware decision-making.

The practical patient question is not “does cannabis treat epilepsy?”. The safer question is: what epilepsy syndrome has been diagnosed, what standard options have already been tried, is there a licensed pathway such as Epidyolex that fits, and what does the epilepsy specialist think is clinically justified?

What treatment-resistant epilepsy usually means

In epilepsy care, treatment-resistant or drug-resistant epilepsy is commonly used when seizures continue despite adequate trials of appropriate anti-seizure medicines. The exact wording and assessment sit with the specialist team, because seizure type, syndrome, age, co-existing conditions and previous treatment history matter.

For patients and carers, the term can feel blunt. It does not mean nothing can be done. A specialist may consider further anti-seizure medicines, dietetic approaches, epilepsy surgery assessment, device-based options, rescue plans, safeguarding, mental-health support, sleep and trigger review, and other syndrome-specific routes.

Cannabis-based medicines sit inside that specialist discussion. They should not replace urgent care plans, rescue medicines, existing anti-seizure medicines, or clinical review.

Where Epidyolex fits

Epidyolex is a cannabidiol oral solution. Its UK product information describes it as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for patients aged 2 years and older. It is also indicated as adjunctive therapy for seizures associated with tuberous sclerosis complex in patients aged 2 years and older.

NICE has separate technology appraisals for cannabidiol with clobazam in Lennox-Gastaut syndrome and Dravet syndrome, and for cannabidiol in tuberous sclerosis complex. Those appraisals set out defined NHS use and conditions. They are not a general endorsement of cannabidiol for every form of epilepsy.

That distinction matters. Epidyolex has a standardised product, product information, clinical-trial evidence for defined indications, monitoring requirements and specialist prescribing context. A private unlicensed cannabis product may have a different composition, different cannabinoid content and a different evidence base.

What NICE and NHS guidance do not support

NICE NG144 is cautious about cannabis-based medicinal products. For epilepsy, it points patients and clinicians toward the specific cannabidiol technology appraisals where they apply. It does not create a broad recommendation for unlicensed CBPMs for seizure disorders outside those defined contexts.

NHS patient guidance also keeps medical cannabis framed as specialist-only and limited. It lists rare, severe forms of epilepsy among the small number of contexts where cannabis-based medicines may be prescribed, but it does not turn that into a general route for all epilepsy.

This means patients should not read “medical cannabis for epilepsy” as a broad promise. The source-backed distinction is between:

  • licensed Epidyolex contexts
  • severe treatment-resistant epilepsy
  • syndrome-specific specialist decision-making
  • unlicensed CBPM boundaries
  • the difference between private legal prescribing and proven benefit

If an unlicensed product is being discussed

Unlicensed cannabis-based medicinal products can be legally prescribed in the UK, but that does not mean they are routine, evidence-equivalent, or suitable for epilepsy. The MHRA specials route is for unlicensed medicines supplied to meet a special clinical need for an individual patient. Professional guidance expects the prescriber to justify the decision, explain uncertainty, monitor outcomes and keep proper records.

For epilepsy, the risk bar is high. Seizure control, medicine interactions, sedation, liver monitoring, cognition, behaviour, school or work, driving, safeguarding and rescue plans can all matter. THC-containing products add extra concerns around impairment and mental-health effects. None of this should be self-managed from an article.

If a clinic or prescriber discusses an unlicensed product, the useful questions are practical and clinical:

  • What exact epilepsy syndrome and seizure types are being treated?
  • Why is a licensed route unsuitable, insufficient or not available in this case?
  • What evidence supports this product for this person, not just for epilepsy in general?
  • How will seizure frequency, rescue medicine use, side effects and quality of life be tracked?
  • What interactions with anti-seizure medicines need checking?
  • What monitoring is planned, including liver tests where relevant?
  • What is the review point if there is no useful response or side effects appear?

What patients and carers can prepare

Preparation should support the specialist conversation, not create a pressure campaign. Useful information may include a seizure diary, current and previous anti-seizure medicines, reasons medicines were stopped, rescue medicine use, hospital letters, current medicines and supplements, previous adverse reactions, and any non-prescribed cannabis or CBD use.

If a private assessment is being explored, the Summary Care Record or relevant specialist letters may help show diagnosis and treatment history. A first eligibility steer can only say whether someone may qualify for assessment. Suitability remains a clinician decision.

Do not stop, reduce or swap anti-seizure medicines without medical advice. Sudden changes can be dangerous for some people with epilepsy.

Safety issues to keep visible

The NHS medical cannabis page lists possible side effects of cannabis-based medicines, including dizziness, tiredness, mood or behaviour changes, hallucinations and suicidal thoughts. It also warns that CBD and THC can affect how other medicines work.

That interaction point is central in epilepsy. Anti-seizure medicines can already have complex effects and monitoring needs. Epidyolex product information includes specialist safety information, including interaction and monitoring considerations. Patients and carers do not need to interpret all of that alone, but they do need to disclose the full medicines list and ask how monitoring works.

Driving needs separate legal and clinical advice. A prescription does not give personal driving clearance. Seizure-control rules and medicine-impairment rules can both matter.

What this means in plain English

There is a real UK cannabis-based medicine pathway in severe epilepsy, but it is specific. Epidyolex is a licensed cannabidiol medicine for defined seizure contexts and specialist use. That is different from saying cannabis-based products generally treat epilepsy.

For patients and carers, the safest next step is a careful specialist conversation: confirm the epilepsy syndrome, understand what has already been tried, ask whether a licensed pathway applies, and ask what evidence and monitoring would support any unlicensed discussion.

Sources

Where to go next

Author picture

Read the eligibility guide for medical cannabis in the UK

Read the eligibility guide

Click here